X0306 4 2022-03-04 0 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0001721442 Sabag Mark C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A ST., TEL AVIV L3 6944020 ISRAEL 0 1 0 0 EVP, International Markets Ordinary Shares 2022-03-04 4 M 0 15920 A 110523 D Ordinary Shares 2022-03-04 4 M 0 43358 A 153881 D Ordinary Shares 2022-03-05 4 M 0 23764 A 177645 D Restricted Share Units 2022-03-04 4 M 0 15920 0.00 D Ordinary Shares 15920 15921 D Restricted Share Units 2022-03-04 4 M 0 43358 0.00 D Ordinary Shares 43358 0 D Restricted Share Units 2022-03-04 4 A 0 134048 0.00 A Ordinary Shares 134048 134048 D Restricted Share Units 2022-03-05 4 M 0 23764 0.00 D Ordinary Shares 23764 71293 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on March 4, 2019, with 15,920 having vested on each of March 4, 2021 and March 4, 2022 and 15,921 vesting on March 4, 2023. Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. Restricted share units were granted on March 4, 2022, with 33,512 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. Restricted share units were granted on March 5, 2021, with 23,764 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 23,765 vesting on March 5, 2025. /s/ Dov Bergwerk as attorney-in-fact for Mark Sabag 2022-03-08